Szczupak Mateusz, Kobak Jacek, Wiśniewska Anna, Kosydar-Bochenek Justyna, Jamro Arkadiusz, Krupa-Nurcek Sabina
Department of Anesthesiology and Intensive Care, Copernicus Hospital, Gdańsk, Poland.
Department of Otolaryngology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Front Med (Lausanne). 2025 Jan 9;11:1519408. doi: 10.3389/fmed.2024.1519408. eCollection 2024.
Opsoclonus-myoclonus syndrome (OMS) is a rare neurological inflammatory disease of paraneoplastic, parainfectious or idiopathic origin. It is manifested by the occurrence of opsoclonus, myoclonus, ataxia, as well as behavioral and sleep disorders. The incidence is estimated at 1/5,000,000 people. This syndrome is usually immune-mediated and may be the first manifestation of cancer as a paraneoplastic syndrome, most often occurring in the course of breast, ovarian or lung cancer. Here we show a case of a 20-year-old woman with symptomatic opsoclonus-myoclonus syndrome in the course of teratoma. A brief review of the literature was conducted to determine the diagnostic route and treatment of this rare condition. As a result, it has been shown that the only method of treatment for OMS syndrome is the removal of the neoplastic lesion.
眼阵挛-肌阵挛综合征（OMS）是一种罕见的具有副肿瘤性、副感染性或特发性病因的神经性炎症性疾病。其表现为眼阵挛、肌阵挛、共济失调以及行为和睡眠障碍。发病率估计为每500万人中有1例。该综合征通常由免疫介导，可能是癌症作为副肿瘤综合征的首发表现，最常见于乳腺癌、卵巢癌或肺癌病程中。在此，我们展示了一例20岁女性在畸胎瘤病程中出现症状性眼阵挛-肌阵挛综合征的病例。为确定这种罕见病症的诊断途径和治疗方法，我们进行了文献简要回顾。结果表明，OMS综合征的唯一治疗方法是切除肿瘤性病变。
